NCT03116126View on ClinicalTrials.gov

Noradrenergic Add-on Therapy With Guanfacine

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

August 5, 2024

Study Completion Date

August 5, 2024

Conditions
Alzheimer Disease
Interventions
DRUG

Guanfacine

2mg oral daily tablet

DRUG

Placebo

inactive oral daily tablet

Trial Locations (1)

W6 8RF

Imperial Memory Unit, Charing Cross Hospital, London

All Listed Sponsors
lead

Imperial College London

OTHER